article thumbnail

PhRMA lies to protect pharma profits

World of DTC Marketing

He leads the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital in Boston. Data were mainly accessible for smaller firms, products in some therapeutic regions, orphan drugs, first-in-class drugs, therapeutic agents that received accelerated approval, and products between 2014 and 2018.

Pharma 255
article thumbnail

What factors are driving life sciences FDI in 2022?

Pharmaceutical Technology

After all, around a third of the world’s leading life sciences corporations have their headquarters in the country. In particular, the area’s unique charm enables it to attract young, college-educated workers, with USA Today dubbing Charleston a ‘millennial magnet’ in 2014 due to its high ratio of millennials to teens.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How one pharma “family business” places patients first

pharmaphorum

The status isn’t awarded lightly and Chiesi is the largest pharmaceutical manufacturer to be named a B Corp. “We We start our meetings by bringing to life a patient testimony and asking the team to reflect on how the goal of each meeting ultimately leads back to the needs of patients,” Chiesi says. “If About the author.

article thumbnail

Call to arms as UK falls back in medicines manufacturing

pharmaphorum

Drastic steps need to be taken if the UK is to reverse a steep decline in medicines manufacturing in recent years, according to a cross-industry coalition. ” Image from the Association of the British Pharmaceutical Industry (ABPI). Notable examples include a pair of 10-year alliances with mRNA specialists Moderna and BioNTech.

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

2 However, most of these efforts relating to catalysis, 3 process waste metrics, 4 lifecycle assessments, 5 pharmaceuticals in the environment 6 and the phase out of substances of concern 7 mainly mitigate the consequences of pharmaceutical manufacturing. Defossilization of pharmaceutical manufacturing.